頁籤選單縮合
題 名 | IL-2引起之毛細血管滲漏症候群=Interleukin-2 (IL-2) Related Capillary Leak Syndrome |
---|---|
作 者 | 盧柏先; 蔡慈貞; | 書刊名 | 藥學雜誌 |
卷 期 | 35:4=141 2019.12[民108.12] |
頁 次 | 頁78-82 |
分類號 | 415.38 |
關鍵詞 | 毛細血管滲漏症候群; 免疫療法; IL-2; Interleukin-2; Capillary leak syndrome; Immunotherapy; |
語 文 | 中文(Chinese) |
中文摘要 | 高劑量介白素-2 (interleukin-2, IL-2) 是第一個被核准用於治療轉移性腎細胞癌及 黑色素癌的免疫療法,可以使少數病人產生持久的抗癌反應並延長其存活時間,不過 高劑量 IL-2 可能會產生毛細血管滲漏症候群,導致毛細血管通透性增加,使體液滲 漏至血管外的組織間隙,另一方面也造成低血容,影響器官灌流甚至導致死亡。不過 這些藥物不良反應是與使用劑量相關、可逆的、可以預期並且也是可以被處理。也因 此高劑量 IL-2仍然是一種有效及安全的治療選擇。 |
英文摘要 | High-dose interleukin-2(IL-2) is the first immunotherapy approved for the treatment of metastatic renal cell carcinoma and melanoma. It has been shown to consistently induce durable responses in a subset of patients leading to long-term survival. However, high dose interleukin-2 may cause capillary leak syndrome. This leads to an increase in the permeability of capillaries, which causes fluids leak into the interstitial space outside the blood vessels. On the other hand, it also causes hypovolemia, affecting organ perfusion and even death. These adverse drug reactions are dose-dependent, reversible, predictable, and manageable. Therefore, high doses of IL-2 remains an effective and safe treatment option. |
本系統中英文摘要資訊取自各篇刊載內容。